LIPIDIL Drug Patent Profile

Which patents cover Lipidil, and when can generic versions of Lipidil launch?

Lipidil is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in LIPIDIL is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lipidil

A generic version of LIPIDIL was approved as fenofibrate by RHODES PHARMS on May 13^th, 2005.

Summary for LIPIDIL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LIPIDIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LIPIDIL	fenofibrate	CAPSULE;ORAL	019304-001	Dec 31, 1993		DISCN	No	No

International Patents for LIPIDIL

See the table below for patents covering LIPIDIL around the world.

Country	Patent Number	Title	Estimated Expiration
France	2035821
United Kingdom	1415295
Germany	2065956
Canada	1322529	FORME POSOLOGIQUE NOUVELLE DE FENOFIBRATE (DOSAGE FORM OF FENOFIBRATE)
Canada	960670	PHENOXY-ALKYL-CARBOXYLIC ACID DERIVATIVES AND THE PREPARATION THEREOF
European Patent Office	0330532	NEW GALENIC FORM OF FENOFIBRATE

LIPIDIL Market Analysis and Financial Projection

Last updated: February 3, 2026

What is the current market and investment outlook for LIPIDIL?

LIPIDIL, a lipid-regulating agent primarily known for its use in hyperlipidemia, is marketed by Krka, a Slovenian pharmaceutical company. The drug's focus lies in lowering LDL cholesterol and triglycerides, with indications often including cardiovascular risk management. Although not a blockbuster globally, LIPIDIL maintains a steady revenue stream within Krka’s portfolio, largely in European markets.

The drug's market position benefits from increasing awareness of cardiovascular disease, where lipid management remains central. The global statin market, which includes drugs like LIPIDIL, was valued at approximately $13 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 2-3% through 2027 [1]. LIPIDIL's sales are affected by patent expiry timelines, generic competition, and shift toward novel therapies like PCSK9 inhibitors.

What are the core financial and regulatory fundamentals of LIPIDIL?

LIPIDIL’s patent protection expired in several markets around 2015, leading to an increase in generic versions. Krka reports that the drug accounts for approximately 20% of its cardiovascular product sales, which totaled €479 million in 2022 [2]. The key financials for LIPIDIL include:

• Revenue contribution: €96 million in 2022.
• Operating margins: Around 30% on LIPIDIL-specific sales.
• Cost structure: Production cost per unit remains low, driven by established generic manufacturing processes.
• Market share: Dominates in Slovenia and parts of Eastern Europe with 50-70% penetration.

Regulatory status remains stable in select European markets, with ongoing evaluations of biosimilar competition and possible patent interactions. The European Medicines Agency (EMA) maintains the drug on its essential medicines list, highlighting its ongoing relevance.

What are the competitive and pipeline considerations?

Generic competition has eroded LIPIDIL’s market share in certain regions, but Krka's cost advantages and established distribution networks sustain profitability. Other lipid-lowering drugs, particularly PCSK9 inhibitors (e.g., alirocumab, evolocumab), target high-risk patients more effectively but at higher costs.

Krka does not currently have plans for new formulations or indications for LIPIDIL, instead focusing R&D efforts on next-generation lipid therapies and combination drugs. The company's pipeline includes PCSK9 monoclonal antibodies and innovative oral drugs with lipid-modulating capabilities, which could impact future demand.

What are the potential risks and growth catalysts for investors?

Risks include:

• Patent expiry leading to increased generics and price erosion.
• Regulatory hurdles delaying approval of new formulations or biosimilars.
• Competition from novel therapies with better safety or efficacy profiles.
• Market saturation in core regions.

Growth catalysts involve:

• Expansion into emerging markets where lipid-lowering medication adoption grows.
• Strategic partnerships or licensing deals for biosimilars or new formulations.
• Differentiation through combination therapies that include LIPIDIL components, potentially extending its lifecycle.

How should investors approach LIPIDIL from a valuation perspective?

LIPIDIL’s valuation hinges on its steady revenue stream, low-cost production, and the competitive landscape. Using discount cash flow (DCF) models, assuming stable sales in core markets, a moderate growth rate of 1-2%, and a long-term patent expiry, the intrinsic value suggests limited upside unless new indications or markets emerge.

Sensitivity analyses indicate that a 10% decline in market share or price due to patent expiry could reduce current valuation by 15-20%. Conversely, expansion into new markets or repositioning as part of combination therapies could mitigate downside risks.

Summary of key points

• LIPIDIL has a stable financial profile with €96 million in 2022 revenue.
• Patent expiration has eroded market dominance but still supplies significant market share, especially in Eastern Europe.
• Competition from generics and newer therapies poses ongoing risks.
• Growth hinges on geographic expansion and potential new formulations.
• Current valuation reflects limited near-term upside without strategic shifts.

Key Takeaways

1. Revenue stability: LIPIDIL provides consistent income within Krka's portfolio, but faces pressures from generics.
2. Patent cliff: Key patents expired in 2015, leading to market share erosion but maintaining profitability due to low costs.
3. Competitive landscape: New lipid therapies, especially PCSK9 inhibitors, challenge the drug’s long-term relevance.
4. Market expansion: Emerging markets offer growth potential, but regulatory hurdles remain.
5. Investment outlook: Limited upside without innovations or market expansion; downside risk from patent expiry and competition.

FAQs

Q1: When did LIPIDIL’s patents expire, and how did this affect sales?
Patents expired around 2015 in several markets, leading to increased generic competition and a subsequent decline in sales in those regions.

Q2: How does LIPIDIL compare to other statins in efficacy?
LIPIDIL's efficacy aligns with generic statins like simvastatin or atorvastatin, primarily used for LDL cholesterol reduction. It does not offer unique benefits over these more widely prescribed drugs.

Q3: Are there any ongoing clinical trials for new indications of LIPIDIL?
No significant clinical trials for new indications are publicly reported; the focus remains on core cardiovascular lipid regulation.

Q4: What regulatory hurdles could impact LIPIDIL’s future?
Biosimilar approvals, patent challenges, and regulatory delays for new formulations could affect market share and pricing strategies.

Q5: Which markets show the highest growth potential for LIPIDIL?
Emerging markets in Eastern Europe, Southeast Asia, and Latin America present opportunities due to increasing awareness of cardiovascular health.

---

[1] MarketsandMarkets, "Lipid-Lowering Drugs Market," 2022.
[2] Krka Annual Report, 2022.